Researchers at the Institute for Antiviral Research at Utah State University tested the company's Halodine nasal and oral antiseptic preparations against the novel coronavirus. They found the solutions were effective against SARS-CoV-2 even when diluted far below available commercial strength, according to Veloce BioPharma.

The Halodine solutions contain a proprietary povidone-iodine antiseptic formulation for repeated nasal and oral use. It is the first iodine-based antiseptic to be active against the novel coronavirus, the lead author noted in a press release.

Proteomics provides insights into SARS-CoV-2 infection, potential therapies
Scientists tested a series of compounds for blocking the replication of SARS-CoV-2 using a novel proteomics approach. The method, which helped identify...

Exyte, Univercells fast track construction for COVID-19 vaccines
High-tech construction firm Exyte and biomanufacturing company Univercells Technologies are partnering for construction of modular standardized and flexible...

Yumab identifies COVID-19 antibody therapy
German biotechnology company Yumab said it has identified a promising candidate for COVID-19 antibody therapy.

Researchers explore role of cytokine storm in severe COVID-19
An overreaction of the immune system to SARS-CoV-2 -- a phenomenon known as cytokine storm -- has emerged as a major contributor to patient mortality...

Neovii, Tel Aviv University partner for COVID-19 vaccine
Israeli firm Ramot has inked a license agreement with Neovii, a Swiss-based biopharmaceutical company, for the research and development of a COVID-19...